Header Logo

CONSTANCE ALBARRACIN

TitleProfessor
InstitutionMD Anderson
DepartmentPathology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2024 Oct 20; 77(11):751-755. PMID: 37586834.
      Citations:    Fields:    
    2. Batra H, Bose PSC, Ding Y, Dai A, Chen H, Albarracin CT, Sun H, Sahin AA, Yang F, Wistuba II, Raso MG. MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers. Histopathology. 2024 Sep; 85(3):503-509. PMID: 38973399.
      Citations:    Fields:    Translation:Humans
    3. Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AA. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat. 2024 Jun; 205(2):403-411. PMID: 38441847.
      Citations:    Fields:    Translation:Humans
    4. Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol. 2024 03; 145:42-47. PMID: 38262580.
      Citations: 2     Fields:    Translation:Humans
    5. Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel). 2023 Dec 19; 16(1). PMID: 38201434; PMCID: PMC10778229.
      Citations:    
    6. Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83. PMID: 37751078.
      Citations:    Fields:    Translation:Humans
    7. Mistretta B, Rankothgedera S, Castillo M, Rao M, Holloway K, Bhardwaj A, El Noafal M, Albarracin C, El-Zein R, Rezaei H, Su X, Akbani R, Shao XM, Czerniecki BJ, Karchin R, Bedrosian I, Gunaratne PH. Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Front Immunol. 2023; 14:1188831. PMID: 37744342; PMCID: PMC10512078.
      Citations:    Fields:    Translation:HumansAnimals
    8. Yang L, Lin H, Shen Y, Roy M, Albarracin C, Ding Q, Huo L, Chen H, Wei B, Bu H, Bedrosian I, Wu Y. Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study. Breast Cancer Res Treat. 2023 Nov; 202(1):23-32. PMID: 37566192.
      Citations:    Fields:    Translation:Humans
    9. Cho WC, Ding Q, Wang WL, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Albarracin CT, Sahin A, Prieto VG, Aung PP. Immunohistochemical expression of TRPS1 in mammary Paget disease, extramammary Paget disease, and their close histopathologic mimics. J Cutan Pathol. 2023 May; 50(5):434-440. PMID: 36808637.
      Citations:    Fields:    Translation:Humans
    10. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated? Clin Breast Cancer. 2023 06; 23(4):415-422. PMID: 36878823.
      Citations:    Fields:    Translation:Humans
    11. Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol. 2022 07; 125:59-67. PMID: 35447141.
      Citations:    Fields:    Translation:Humans
    12. Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol. 2022 07; 125:97-107. PMID: 35413381.
      Citations:    Fields:    Translation:Humans
    13. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022 03; 121:73-80. PMID: 35063444.
      Citations:    Fields:    Translation:Humans
    14. Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian I. Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Res Treat. 2021 Jun; 187(2):363-374. PMID: 33893908; PMCID: PMC8190001.
      Citations: 2     Fields:    Translation:Animals
    15. McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat. 2021 May; 187(1):95-104. PMID: 33813685.
      Citations: 1     Fields:    Translation:Humans
    16. Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel). 2021 Apr 01; 13(7). PMID: 33916118; PMCID: PMC8036262.
      Citations: 2     
    17. Kilgore LJ, Yi M, Bevers T, Coyne R, Marita L, Lane D, Albarracin C, Bedrosian I. Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision. Ann Surg. 2022 12 01; 276(6):e932-e936. PMID: 33914469.
      Citations:    Fields:    
    18. Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat. 2021 Apr; 186(2):403-415. PMID: 33528758.
      Citations: 6     Fields:    Translation:Humans
    19. Roy M, Teshome M, Damodaran S, Sahin AA, Khazai L, Arribas E, Candelaria RP, Scoggins ME, Lane DL, Giordano SH, Albarracin CT, Prieto VG, Nagarajan P. Male Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol. 2020 Dec; 42(12):981-985. PMID: 33289978.
      Citations:    Fields:    Translation:Humans
    20. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021 04; 34(4):710-719. PMID: 33011748.
      Citations: 4     Fields:    Translation:Humans
    21. Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ. Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):303-307. PMID: 32033821; PMCID: PMC7340565.
      Citations:    Fields:    Translation:Humans
    22. Asik E, Caner A, Kahraman N, Guray T, Albarracin C, Pataer A, Ozpolat B, Akpinar Y, Volkan M, Arun B. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338. PMID: 31432749.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    23. Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJ. Not all patients with a diagnosis of a radial scar require excision. Breast J. 2019 07; 25(4):792-794. PMID: 31087426.
      Citations: 1     Fields:    Translation:Humans
    24. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157. PMID: 28742682; PMCID: PMC6051916.
      Citations: 12     Fields:    Translation:Humans
    25. Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 12 11; 20(1):150. PMID: 30537987; PMCID: PMC6290546.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    26. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. PMID: 30139837; PMCID: PMC6291334.
      Citations: 20     Fields:    Translation:Humans
    27. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109. PMID: 29470805; PMCID: PMC5994186.
      Citations: 10     Fields:    Translation:Humans
    28. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662. PMID: 28928852; PMCID: PMC5604195.
      Citations: 14     
    29. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34. PMID: 28608612; PMCID: PMC5729065.
      Citations: 12     Fields:    Translation:Humans
    30. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    31. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857. PMID: 28125801; PMCID: PMC5355228.
      Citations: 7     Fields:    Translation:HumansCells
    32. Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol. 2017 Jan; 24(1):70-76. PMID: 27573525; PMCID: PMC6130894.
      Citations: 6     Fields:    Translation:Humans
    33. Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJ. Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation. Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):130-135. PMID: 26949063.
      Citations: 7     Fields:    Translation:Humans
    34. Miller T, Albarracin C, Carkaci S, Whitman GJ, Adrada BE. Rare Malignant Tumors of the Breast. J Clin Imaging Sci. 2015; 5:58. PMID: 26664775; PMCID: PMC4647127.
      Citations: 1     
    35. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7. PMID: 26280679; PMCID: PMC4829956.
      Citations: 17     Fields:    Translation:Humans
    36. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015 Jun 25; 17:87. PMID: 26108797; PMCID: PMC4480452.
      Citations:    Fields:    
    37. Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678. PMID: 26000884; PMCID: PMC4441370.
      Citations: 22     Fields:    Translation:HumansCells
    38. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7. PMID: 25975189.
      Citations: 3     Fields:    Translation:Humans
    39. Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R, Symmans WF. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 2015 Jul; 28(7):913-20. PMID: 25932963; PMCID: PMC4830087.
      Citations: 31     Fields:    Translation:Humans
    40. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. PMID: 25878190; PMCID: PMC6267938.
      Citations: 28     Fields:    Translation:Humans
    41. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2580-90. PMID: 25739674; PMCID: PMC4452384.
      Citations: 106     Fields:    Translation:HumansAnimalsCells
    42. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol. 2014 Sep; 45(9):1951-6. PMID: 25074542.
      Citations: 6     Fields:    Translation:HumansCells
    43. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS One. 2014; 9(5):e97076. PMID: 24811059; PMCID: PMC4014598.
      Citations: 7     Fields:    Translation:HumansCells
    44. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72. PMID: 24796968; PMCID: PMC4224140.
      Citations: 8     Fields:    Translation:Humans
    45. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014 Mar 04; 14:147. PMID: 24589259; PMCID: PMC3974013.
      Citations: 44     Fields:    Translation:HumansPHPublic Health
    46. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417. PMID: 25551582; PMCID: PMC4326485.
      Citations: 13     Fields:    Translation:HumansCells
    47. Krishnamurthy S, Mathews K, McClure S, Murray M, Gilcrease M, Albarracin C, Spinosa J, Chang B, Ho J, Holt J, Cohen A, Giri D, Garg K, Bassett RL, Liang K. Multi-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Arch Pathol Lab Med. 2013 Dec; 137(12):1733-9. PMID: 23947655.
      Citations: 18     Fields:    Translation:Humans
    48. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8. PMID: 22895267.
      Citations: 3     Fields:    Translation:Humans
    49. Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L. The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol. 2013 Jan; 26(1):71-8. PMID: 22899286; PMCID: PMC3881416.
      Citations: 4     Fields:    Translation:Humans
    50. Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS, Marchi? C. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology. 2012 May; 60(6B):E115-30. PMID: 22486256.
      Citations: 15     Fields:    Translation:Humans
    51. Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Fuller GN. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Ann Diagn Pathol. 2012 Aug; 16(4):255-9. PMID: 22445362.
      Citations: 3     Fields:    Translation:Humans
    52. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41. PMID: 22392043; PMCID: PMC3855009.
      Citations: 5     Fields:    Translation:Humans
    53. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. 2012 Oct 04; 31(40):4372-83. PMID: 22231447; PMCID: PMC3326223.
      Citations: 30     Fields:    Translation:HumansCells
    54. Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Goodman JC, Fuller GN. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol. 2012 Jun; 16(3):161-70. PMID: 22197544.
      Citations: 14     Fields:    Translation:Humans
    55. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology. 2011 Oct; 59(4):619-30. PMID: 22014043.
      Citations: 14     Fields:    Translation:Humans
    56. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46. PMID: 21900106; PMCID: PMC4874218.
      Citations: 62     Fields:    Translation:Humans
    57. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22. PMID: 22009639; PMCID: PMC4407692.
      Citations: 9     Fields:    Translation:Humans
    58. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53. PMID: 21830012; PMCID: PMC4334122.
      Citations: 35     Fields:    Translation:Humans
    59. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15. PMID: 21668471.
      Citations: 14     Fields:    Translation:Humans
    60. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5. PMID: 21482991.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    61. Shehu A, Albarracin C, Devi YS, Luther K, Halperin J, Le J, Mao J, Duan RW, Frasor J, Gibori G. The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells. Mol Endocrinol. 2011 May; 25(5):754-66. PMID: 21372145; PMCID: PMC3082328.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    62. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77. PMID: 21334720.
      Citations: 20     Fields:    Translation:HumansCells
    63. Whitman GJ, Albarracin CT, Gonzalez-Angulo AM. Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol. 2011 Jan; 46(1):26-39. PMID: 21134526.
      Citations: 7     Fields:    Translation:Humans
    64. Albarracin CT, Nguyen CV, Whitman GJ, Yang W, Weiang W, Sneige N. Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy. Radiology. 2010 Dec; 257(3):893-4; author reply 984. PMID: 21084420.
      Citations:    Fields:    Translation:Humans
    65. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010 Nov 16; 18(5):423-35. PMID: 21075308; PMCID: PMC3022383.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    66. Resetkova E, Khazai L, Albarracin CT, Arribas E. Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J. 2010 Nov-Dec; 16(6):573-80. PMID: 21070433.
      Citations: 8     Fields:    Translation:Humans
    67. Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol. 2011 Mar; 18(3):752-61. PMID: 20972636.
      Citations: 23     Fields:    Translation:Humans
    68. Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee P. Distinct function of androgen receptor coactivator ARA70a and ARA70? in mammary gland development, and in breast cancer. Breast Cancer Res Treat. 2011 Jul; 128(2):391-400. PMID: 20814820.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    69. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010 Jul 01; 116(13):3084-92. PMID: 20564633; PMCID: PMC3041268.
      Citations: 12     Fields:    Translation:Humans
    70. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163. PMID: 20121597.
      Citations: 1     Fields:    Translation:Humans
    71. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009 Dec; 20(12):1953-8. PMID: 19596702; PMCID: PMC2791352.
      Citations: 117     Fields:    Translation:Humans
    72. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009 Apr; 33(4):534-41. PMID: 19047898.
      Citations: 16     Fields:    Translation:HumansCells
    73. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009 May; 174(5):1940-8. PMID: 19342367; PMCID: PMC2671281.
      Citations: 74     Fields:    Translation:Humans
    74. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7. PMID: 19174581; PMCID: PMC4520422.
      Citations: 11     Fields:    Translation:Humans
    75. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009 Apr; 20(4):621-7. PMID: 19150943; PMCID: PMC2722369.
      Citations: 66     Fields:    Translation:Humans
    76. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. PMID: 19064970.
      Citations: 56     Fields:    Translation:HumansAnimals
    77. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009 Jan 10; 27(2):220-6. PMID: 19047281; PMCID: PMC4516695.
      Citations: 46     Fields:    Translation:Humans
    78. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008 Dec; 16(6):530-4. PMID: 18776816.
      Citations: 19     Fields:    Translation:Humans
    79. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8. PMID: 18779615; PMCID: PMC6366335.
      Citations: 212     Fields:    Translation:Humans
    80. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6. PMID: 18176935; PMCID: PMC2580832.
      Citations: 119     Fields:    Translation:Humans
    81. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008 Nov 06; 27(52):6667-78. PMID: 18663355.
      Citations: 106     Fields:    Translation:HumansCells
    82. Resetkova E, Edelweiss M, Albarracin CT, Yang WT. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat. 2011 Jun; 127(2):335-43. PMID: 18626769.
      Citations: 10     Fields:    Translation:Humans
    83. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol. 2008 Apr; 32(4):544-52. PMID: 18300793.
      Citations: 20     Fields:    Translation:Humans
    84. Albarracin CT, Resetkova E, Ferreira M. Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol. 2008 Feb; 21(2):201-7. PMID: 18084246.
      Citations: 25     Fields:    Translation:HumansCells
    85. Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007 Dec; 15(4):451-5. PMID: 18091390.
      Citations: 24     Fields:    Translation:Humans
    86. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R. Development of new cancers in patients with DCIS: the M.D. Anderson experience. Ann Surg Oncol. 2008 Jan; 15(1):244-9. PMID: 18043978.
      Citations: 3     Fields:    Translation:Humans
    87. May SA, Deavers MT, Resetkova E, Johnson D, Albarracin CT. Giant cell tumor of soft tissue arising in breast. Ann Diagn Pathol. 2007 Oct; 11(5):345-9. PMID: 17870021.
      Citations: 8     Fields:    Translation:Humans
    88. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67. PMID: 17211865.
      Citations: 92     Fields:    Translation:Humans
    89. He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JL. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther. 2007 Jan; 6(1):76-82. PMID: 17172821.
      Citations: 22     Fields:    Translation:HumansCells
    90. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006 Oct 15; 107(8):1760-8. PMID: 16977650.
      Citations: 25     Fields:    Translation:Humans
    91. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604. PMID: 16899607.
      Citations: 44     Fields:    Translation:Humans
    92. Anderson P, Albarracin CT, Resetkova E. A large, fungating breast mass. Secretory carcinoma with apocrine differentiation. Arch Pathol Lab Med. 2006 Apr; 130(4):e50-2. PMID: 16594759.
      Citations: 4     Fields:    Translation:Humans
    93. Resetkova E, Albarracin C, Sneige N. Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature. Am J Surg Pathol. 2006 Jan; 30(1):20-7. PMID: 16330938.
      Citations: 11     Fields:    Translation:Humans
    94. Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):178-82. PMID: 16445630.
      Citations: 3     Fields:    Translation:HumansCells
    95. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69. PMID: 16322343.
      Citations: 21     Fields:    Translation:Humans
    96. Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep. 2004 Dec; 12(6):1217-9. PMID: 15547740.
      Citations: 3     Fields:    Translation:HumansCells
    97. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Marcelo AC, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat. 2004 Oct; 87(3):205-14. PMID: 15528963.
      Citations: 24     Fields:    Translation:HumansCells
    98. Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004 May; 35(5):552-9. PMID: 15138928.
      Citations: 41     Fields:    Translation:HumansCells
    99. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004 Jan; 17(1):75-80. PMID: 14631366.
      Citations: 19     Fields:    Translation:HumansCells
    100. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2000 Jun; 31(6):672-7. PMID: 10872659.
      Citations: 20     Fields:    Translation:Humans
    101. Albarracin CT, Palfrey HC, Duan WR, Rao MC, Gibori G. Prolactin regulation of the calmodulin-dependent protein kinase III elongation factor-2 system in the rat corpus luteum. J Biol Chem. 1994 Mar 11; 269(10):7772-6. PMID: 8126003.
      Citations: 1     Fields:    Translation:AnimalsCells
    102. Rare Malignant Tumors of the Breast. Journal of Clinical Imaging Science. 5.
    103. Pseudoangiomatous Stromal Hyperplasia of the Breast. Current Problems in Diagnostic Radiology.
    104. Erratum to. Breast Cancer Research. 17.
    105. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clinical Cancer Research. 21:2580-2590.
    106. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research. 16.
    107. Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PLoS One. 10.
    108. Multi-institutional comparison of Whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Archives of Pathology and Laboratory Medicine. 137:1733-1739.
    109. Ki67 as a Biomarker of Prognosis and Prediction. Current Breast Cancer Reports. 6:260-266.
    110. Erratum. Cancer. 120:927.
    111. Immunological and molecular studies in breast tumors. 209-243.
    112. Erratum. Breast Cancer Research and Treatment. 89:95.
    113. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Modern Pathology.
    114. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Annals of Surgical Oncology. 1-7.
    115. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Breast Diseases. 22:383-384.
    ALBARRACIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (399)
    Explore
    _
    Co-Authors (119)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _